ARS Pharmaceuticals (SPRY) Other Non-Current Liabilities (2021 - 2026)

ARS Pharmaceuticals (SPRY) reported Other Non-Current Liabilities of $4.5 million for Q1 2026, down 2.76% sequentially from $4.6 million in Q4 2025.

ARS Pharmaceuticals (SPRY) Other Non-Current Liabilities (2021 - 2026) Analysis & Trends

ARS Pharmaceuticals (SPRY) has 3 years of Other Non-Current Liabilities data on file, last reported at $4.5 million in Q1 2026.

For the quarter ending Q1 2026, Other Non-Current Liabilities changed N/A year-over-year to $4.5 million; the trailing twelve-month figure through Mar 2026 stood at $4.5 million (changed N/A YoY), and the FY2025 full-year result was $4.6 million, changed N/A from the prior year.
Other Non-Current Liabilities fell to $4.5 million in Q1 2026, from $4.6 million in the prior quarter.
In the past five years, Other Non-Current Liabilities ranged from a high of $4.6 million in Q4 2025 to a low of $1.4 million in Q2 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	67,072.09 Bn	67,072.09 Bn	-
2	Nanobiotix	1,894.61 Bn	1,894.55 Bn	-
3	Akari Therapeutics	1,014.18 Bn	1,014.18 Bn	-
4	BeOne Medicines	471.64 Bn	466.85 Bn	1.35 Bn
5	Vertex Pharmaceuticals	121.72 Bn	114.47 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	68.28 Bn	59.52 Bn	3.31 Bn
7	Belite Bio	61.40 Bn	61.40 Bn	-
8	Argenx Se	56.94 Bn	56.94 Bn	1.18 Bn
9	Revolution Medicines	37.37 Bn	37.37 Bn	-
10	ARS Pharmaceuticals	595.78 Mn	394.81 Mn	-

Download Data